Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Severe Anemia Is Associated with a Risk of Infection in Patients with Myelodysplastic Syndromes

Annika Kasprzak, Julia Andresen, Barbara Hildebrandt, Kathrin Nachtkamp, Andrea Kündgen, Guido Kobbe, Norbert Gattermann, Ulrich Germing

Blood (2021) 138 (Supplement 1): 4668.

https://doi.org/10.1182/blood-2021-151288

Published: 2021

Journal Articles

Increased Bone Marrow Iron at Diagnosis Is Associated with Inferior Prognosis in Patients with Myelodysplastic Syndromes

Annika Kasprzak, Sandra Becker, Martina Rudelius, Corinna Strupp, Kathrin Nachtkamp, Judith Strapatsas, Barbara Hildebrandt, Norbert Gattermann, Ulrich Germing

Blood (2021) 138 (Supplement 1): 3700.

https://doi.org/10.1182/blood-2021-152402

Published: 2021

Journal Articles

Mutation Profile of PPM1D and TP53 in Patients with Myelodysplastic Syndromes and Complex Chromosome Abnormalities

Blood (2019) 134 (Supplement_1): 2994.

https://doi.org/10.1182/blood-2019-126778

Published: 2019

Journal Articles

TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (≥3 anomalies) Aberrant Karyotypes

Blood (2019) 134 (Supplement_1): 3007.

https://doi.org/10.1182/blood-2019-126671

Published: 2019

Journal Articles

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Andrea Kuendgen, MD, Meritxell Nomdedeu, Heinz Tuechler, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, Alan F. List, MD, Mario Cazzola, Amy E. DeZern, MD, Gail J. Roboz, MD, David P. Steensma, MD, Arjan A. Van de Loosdrecht, MD PhD, Hartmut Döhner, MD, Xavier Calvo, MD, Sabine Blum, Arturo Pereira, MD PhD, Peter Valent, Dolors Costa, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, Carme Pedro, MD, Michael Lübbert, Itziar Oiartzabal, Javier Grau, Maria Díez-Campelo, María Teresa Cedena, Sigrid Machherndl-Spandl, MD, Maria López-Pavía, Claudia D. Baldus, MD, Montserra Martinez-de-Sola, Reinhard Stauder, MD MSc, Brayan Merchan, Christina Ganster, Thomas Schroeder, Barbara Hildebrandt, Jordi Esteve, MD PhD, Benet Nomdedeu, Francesc Cobo, Francesc Sole, PhD, Rainer Haas, MD, Ulrich Germing, MD, Peter L Greenberg, MD, Detlef Haase, MD PhD, Guillermo Sanz

Blood (2018) 132 (Supplement 1): 3103.

https://doi.org/10.1182/blood-2018-99-118215

Published: 2018

Journal Articles

Quantitative Next-Generation Sequencing (NGS) Based Monitoring of Minimal Residual Disease (MRD) Predicts Imminent Relapse in Patients with Myeloid Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Christina Rautenberg, MD, Beate Betz, Dagmar Wieczorek, Barbara Hildebrandt, Kathrin Nachtkamp, MD, Esther Schuler, Norbert Gattermann, MD, Guido Kobbe, MD, Rainer Haas, MD, Thomas Schroeder, MD

Blood (2017) 130 (Supplement 1): 2005.

https://doi.org/10.1182/blood.V130.Suppl_1.2005.2005

Published: 2017

Journal Articles

Comparison Between Wilms' Tumor 1 (WT1) Expression Using a Standardized European Leukemia Net (ELN)-Certified Assay and Other Methods for Detection of Minimal Residual Disease (MRD) in MDS and AML Patients after Allogeneic Blood Stem Cell Transplantation

Christina Rautenberg, MD, Sabrina Pechtel, Barbara Hildebrandt, Beate Betz, Ariane Dienst, MD, Kathrin Nachtkamp, MD, Stefanie Geyh, Pia Verena Schmidt, MD, Claudia Heyn, MD, Mustafa Kondakci, MD, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing, Guido Kobbe, MD, Thomas Schroeder, MD

Blood (2016) 128 (22): 3447.

https://doi.org/10.1182/blood.V128.22.3447.3447

Published: 2016

Journal Articles

Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine

Andrea Kuendgen, MD, Catharina Müller-Thomas, MD, Petra Urbaniak, Michael Lauseker, Torsten Haferlach, MD, Tamara Alpermann, Andreia Albuquerque, PhD, Alexander Kohlmann, PhD, Susanne Schnittger, PhD, Barbara Hildebrandt, PhD, Brigitte Royer-Pokora, PhD, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing, MD, Katharina Götze, MD

Blood (2013) 122 (21): 2757.

https://doi.org/10.1182/blood.V122.21.2757.2757

Published: 2013

Journal Articles

Prognostic Impact Of Molecular Mutations In 182 Patients With Myelodysplastic Syndromes

Andrea Kuendgen, MD, Jenny Seidler, Michael Lauseker, Torsten Haferlach, MD, Susanne Schnittger, PhD, Alexander Kohlmann, PhD, Barbara Hildebrandt, PhD, Catharina Müller-Thomas, MD, Beate Betz, PhD, Rainer Haas, MD, Norbert Gattermann, MD, Brigitte Royer-Pokora, PhD, Katharina Götze, M.D., Ulrich Germing, MD

Blood (2013) 122 (21): 2758.

https://doi.org/10.1182/blood.V122.21.2758.2758

Published: 2013

Journal Articles

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia

Esperanza Such, Ulrich Germing, Luca Malcovati, José Cervera, Andrea Kuendgen, Matteo G. Della Porta, Benet Nomdedeu, Leonor Arenillas, Elisa Luño, Blanca Xicoy, Mari L. Amigo, David Valcarcel, Kathrin Nachtkamp, Ilaria Ambaglio, Barbara Hildebrandt, Ignacio Lorenzo, Mario Cazzola, Guillermo Sanz

Blood (2013) 121 (15): 3005–3015.

https://doi.org/10.1182/blood-2012-08-452938

Published: 2013

Includes: Supplemental data

Journal Articles

Prognostic Impact of Monosomy 7 as a Single Anomaly In Primary MDS – Reclassification From Poor to Intermediate Prognosis

Julie Schanz, MD, Heinz Tüchler, Francesc Sole, Mar Mallo, Barbara Hildebrandt, Christian Steidl, MD, Christa Fonatsch, Michael Pfeilstöcker, MD, Thomas Nösslinger, MD, Peter Valent, Aristoteles Giagounidis, Michael Lübbert, MD, Reinhard Stauder, Otto Krieger, M.D., Michelle M. Le Beau, PhD, John M. Bennett, MD, Peter L. Greenberg, MD, Ulrich Germing, Detlef Haase

Blood (2010) 116 (21): 1861.

https://doi.org/10.1182/blood.V116.21.1861.1861

Published: 2010

Journal Articles

Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality?

Blood (2010) 116 (21): 4008.

https://doi.org/10.1182/blood.V116.21.4008.4008

Published: 2010

Journal Articles

Unrelated Clones In Myelodysplastic Syndromes and Acute Myeloid Leukemia - Characterization and Prognostic Relevance

Blood (2010) 116 (21): 4022.

https://doi.org/10.1182/blood.V116.21.4022.4022

Published: 2010

Journal Articles

Will a Peripheral Blood (PB) Sample Yield the Same Diagnostic and Prognostic Cytogenetic Data as the Concomitant Bone Marrow (BM) In Myelodysplasia? An International Study Comparing Cytogenetics and Interphase FISH Using Parallel PB and BM Samples

Athena M Cherry, Ph.D., Marilyn L. Slovak, PhD, Lynda J Campbell, MBBS, FRCPA, Kathy Chun, PhD, Virginie Eclache, Detlef Haase, Claudia Haferlach, MD, Anne Hagemeijer, MD, Barbara Hildebrandt, Anwar M. Iqbal, PhD, Suresh C. Jhanwar, PhD, Michelle Lebeau, Kazuma Ohyashiki, MD, PhD, Francesc Solé, PhD, Daniel L. Van Dyke, PhD, Gordon Dewald

Blood (2010) 116 (21): 2922.

https://doi.org/10.1182/blood.V116.21.2922.2922

Published: 2010

Journal Articles

Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).

Blood (2009) 114 (22): 945.

https://doi.org/10.1182/blood.V114.22.945.945

Published: 2009

Journal Articles

Cytogenetic Risk Features in MDS-Update and Present State.

Blood (2009) 114 (22): 2772.

https://doi.org/10.1182/blood.V114.22.2772.2772

Published: 2009

Journal Articles

Varying Importance of Prognostic Factors in Subgroups of Myelodysplastic Syndromes Defined by Blast Count, Cytogenetic Risk Group, or WHO Classification.

Andrea Kuendgen, Corinna Strupp, Kathrin Nachtkamp, Barbara Hildebrandt, Rainer Haas, Norbert Gattermann, Ulrich Germing

Blood (2009) 114 (22): 2776.

https://doi.org/10.1182/blood.V114.22.2776.2776

Published: 2009

Journal Articles

New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics

Julie Schanz, Marilyn L. Slovak, Kazuma Ohyashiki, Francesc Solé, Maria del Mar Mallo, Christian Steidl, Michael Pfeilstoecker, Thomas Noesslinger, Barbara Hildebrandt, Michael Luebbert, Mette K Andersen, Aristoteles Giagounidis, Peter Valent, Christa Fonatsch, Ulrich Germing, Detlef Haase

Blood (2008) 112 (11): 2688.

https://doi.org/10.1182/blood.V112.11.2688.2688

Published: 2008

Journal Articles

Characteristics of Disease Progression in 3213 Patients with Myelodysplastic Syndrome

Fabian Zohren, Corinna Strupp, Andrea Kuendgen, Aristoteles Giagounidis, Barbara Hildebrandt, Ulrich Suter, Norbert Gattermann, MD, Rainer Haas, Ulrich Germing

Blood (2008) 112 (11): 2689.

https://doi.org/10.1182/blood.V112.11.2689.2689

Published: 2008

Journal Articles

Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome.

Blood (2008) 112 (11): 1649.

https://doi.org/10.1182/blood.V112.11.1649.1649

Published: 2008

NARROW

Severe Anemia Is Associated with a Risk of Infection in Patients with Myelodysplastic Syndromes

Increased Bone Marrow Iron at Diagnosis Is Associated with Inferior Prognosis in Patients with Myelodysplastic Syndromes

Mutation Profile of PPM1D and TP53 in Patients with Myelodysplastic Syndromes and Complex Chromosome Abnormalities

TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (≥3 anomalies) Aberrant Karyotypes

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Quantitative Next-Generation Sequencing (NGS) Based Monitoring of Minimal Residual Disease (MRD) Predicts Imminent Relapse in Patients with Myeloid Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Comparison Between Wilms' Tumor 1 (WT1) Expression Using a Standardized European Leukemia Net (ELN)-Certified Assay and Other Methods for Detection of Minimal Residual Disease (MRD) in MDS and AML Patients after Allogeneic Blood Stem Cell Transplantation

Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine

Prognostic Impact Of Molecular Mutations In 182 Patients With Myelodysplastic Syndromes

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia

Prognostic Impact of Monosomy 7 as a Single Anomaly In Primary MDS – Reclassification From Poor to Intermediate Prognosis

Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality?

Unrelated Clones In Myelodysplastic Syndromes and Acute Myeloid Leukemia - Characterization and Prognostic Relevance

Will a Peripheral Blood (PB) Sample Yield the Same Diagnostic and Prognostic Cytogenetic Data as the Concomitant Bone Marrow (BM) In Myelodysplasia? An International Study Comparing Cytogenetics and Interphase FISH Using Parallel PB and BM Samples

Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).

Cytogenetic Risk Features in MDS-Update and Present State.

Varying Importance of Prognostic Factors in Subgroups of Myelodysplastic Syndromes Defined by Blast Count, Cytogenetic Risk Group, or WHO Classification.

New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics

Characteristics of Disease Progression in 3213 Patients with Myelodysplastic Syndrome

Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only